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During  recent  years  intensive  research  has been  focused  on  the synthesis  of structurally  modiﬁed  steroid
hormones  in order to obtain  compounds  with  beneﬁcial  biological  activity  such  as  cell-growth  inhibi-
tion.  Experimental  results  have  revealed  that  some  steroidal  derivatives  possess  direct  cytostatic  effect
on  cancer  cells  in  a hormone  receptor-independent  manner.  After  a brief account  on  the  most  impor-
tant  biological  function  and  characteristics  of the  naturally  occurring  sex  hormones  in  physiological
and  pathological  conditions,  structural  modiﬁcations  of  estrane  and androstane  scaffolds  are  discussedodiﬁed sex hormones
ynthesis
ntiproliferative activity
in detail.  The  review  covers  literature  publications  (from  2002  to  2012)  relating  to the  synthesis  and
antiproliferative  activity  of semisynthetic  sex  hormone-derived  molecules  containing  simple  or  hetero-
cyclic  substituents.  The  compounds  reviewed  are  divided  into  three  main  categories  according  to their
sterane  framework  and  the  nature  of  substitution.
This  article  is  part  of  a Special  Issue  entitled  “Synthesis  and  biological  testing  of steroid  derivatives  as
inhibitors”.
© 2013 Published by Elsevier Ltd.
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. Introduction
Natural sex hormones, i.e. androgens, estrogens and progesto-
ens, which are produced primarily by the gonads and in smaller
mounts by the adrenal glands and other tissues, exert a wide range
f biological effects on the body, affecting the growth and function
f the reproductive organs and the development of secondary sex-
framework, steroid hormones can easily penetrate through the cell
membranes and interact with their speciﬁc intracellular recep-
tors, either in the cytosol or in the nucleus of the target cells.
Through this slow genomic mechanism, the ligand–receptor com-
plex acts as a transcription factor in the nucleus, augmenting or
suppressing particular transcription genes by its action on DNA
[1]. Recent studies suggest, however, that the effects of steroidal characteristics. Androgens are also the original anabolic steroids
nd the precursors of all estrogens, which (together with proges-
erone) play a major role in the regulation of the menstrual cycle
nd pregnancy. Thanks to their nonpolar and hydrophobic sterane
∗ Corresponding author. Tel.: +36 62 544276; fax: +36 62 544200.
E-mail address: schneider@chem.u-szeged.hu (G. Schneider).
960-0760/$ – see front matter ©  2013 Published by Elsevier Ltd.
ttp://dx.doi.org/10.1016/j.jsbmb.2013.02.018hormones can also be mediated by fast nongenomic mechanisms
through membrane-associated receptors and signaling cascades
[2]. As a result of extensive structure–activity relationship (SAR)
studies, a considerable amount of information is available con-
cerning the structural features of the intracellular receptors, the
pharmacophore moiety of the ligands and hormone–receptor bind-
ing [3–5]. Besides hydrophobic interactions, hydrogen-bonding in
some regions of the steroid binding pocket is also involved in the
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Scheme 1. Synthesis of D-ring-unsaturated analogs of 2ME2.  Reagents and conditions: (i) BnBr, K2CO3, DMF; (ii) isopropenyl acetate, Ac2O, TsOH; (iii) NaBH4, MeOH, THF, H2O;
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civ)  Ac2O, NaOH, iPrOH, H2O; (v) Jones reagent, acetone; (vi) HS(CH2)2SH, BF3·OEt2
eOH;  (xi) nBuLi, THF.
inding mechanism. All semisynthetic modiﬁcations involving the
polar sterane skeleton or the polar functional groups at C-3 and
-17 in the natural hormones may  exert a signiﬁcant inﬂuence on
he binding afﬁnity of the molecule.
In consequence of the important functions of steroid hormones,
hey and their modiﬁed analogs have been applied exogenously
o humans in order to attain certain beneﬁts in health or even
o improve physical and growth performance. Estrogens and pro-
estogens are administered as components of oral contraceptives
nd in hormone replacement therapy, while androgens are used
o correct natural hormone deﬁciencies and to reduce “male
enopause” symptoms such as the lack of sex drive, anxiety
nd depression. Furthermore, extensive effort has been devoted
o the synthesis of potentially therapeutic derivatives provid-
ng enhanced anabolic potency with reduced androgenic effects,
hough with only modest success [4].
In addition to the modulation of normal development and main-
enance of the reproductive tract, sex steroids play a crucial role
n the malignant growth of these organs [6]. As steroid hormones
re powerful drivers of the gene expression in hormone-dependent
ancer cells, changes in the levels or activities of certain hormones; (vii) Raney Ni, acetone; (viii) K2CO3, MeOH, H2O; (ix) LiAlH4, Et2O; (x) TsNHNH2,
can cause these cancers to cease growing, or even undergo cell
death. Hormonal therapy is therefore one of the major possibili-
ties for the medical treatment of cancer, involving manipulation
of the endocrine system through the exogenous administration of
steroid hormones, or drugs which inhibit the production or activ-
ity of the endogenous ligand. Thus, a number of modiﬁed steroid
molecules have been described as potent inhibitors of speciﬁc
enzymes involved in the biosynthesis of sex hormones, allow-
ing their potential use in the medication of hormone-dependent
diseases. Steroidal exo-heterocycles, for example, such as the the-
rapeutically used abiraterone, can block androgen synthesis at an
early stage by inhibiting 17-hydroxylase/C17,20-lyase (P45017)
and can therefore be effective in the treatment of prostate can-
cer [7–11]. Moreover, some drugs exert their biological activity
as aromatase inhibitors by reducing estrogen production and can
thus be applied in the treatment of estrogen receptor-positive
(ER+) breast cancer [12,13]. Another approach in cancer therapy
is the application of antagonists which bind to the receptor of a
given hormone, thereby preventing its activation. However, the
effectiveness of these drugs is limited by their partial agonist prop-
erties, which can cause undesirable side-effects [14]. Experimental
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fcheme 2. Synthesis of 18a-homoanalogs of 2ME2.  Reagents and conditions:  (i) NaB
a2HPO3, CH2Cl2; (vi) NaOH, MeOH, H2O; (vii) LiOH·H2O, Me2SO4, THF; (viii) H2, Pd
esults achieved during the past few years have revealed that some
teroidal derivatives play important roles in complex signal trans-
uction mechanisms in a hormone receptor-independent manner
y the inhibition of angiogenesis, tubulin polymerization and the
pregulation of apoptotic pathways. The main advantage of this
ode of action is that such compounds may  offer a solution for
he therapy of hormone-resistant cancers. The most important
andidate in this class is 2-methoxyestradiol (2ME2), an endoge-
ous metabolite of 17-estradiol, which has been shown to be
ffective in preventing tumor growth in a variety of cell lines of
iverse origins [15–21]. Although the exact mechanism of action
s still unclear, the unique antiproliferative and apoptotic activi-
ies of 2ME2 are mediated independently of the estrogen receptors
22,23].
A major challenge in semisynthetic steroid chemistry at present
s the development of novel derivatives with a biological target
ther than a hormone receptor, and therefore the reduction or elim-
nation of undesirable hormonal activity. The synthetic tools for the
ttainment of this goal are: (a) the synthesis of molecules lacking
he functionalities necessary for effective binding to the hormone
eceptors [24]; (b) modiﬁcation of the binding ability by chemi-
al transformation of the functional groups already present [3]; (c)
teric hindrance of the substrate-receptor interaction by chemical
ubstitution near the original groups [19]; (d) altering the primary
tereostructure or the number of ring members [25]; and (e) the
esign of heterocyclic derivatives that are not recognized by the
eceptor protein in consequence of their speciﬁc structure or the
act that their geometry differs from that of the natural hormonesOH, H2O; (ii) Ac2O, pyridine; (iii) ZrCl4, CH2Cl2; (iv) BnBr, K2CO3, DMF; (v) MCPBA,
OH; (ix) NaH/THF, MeI; (x) H2, Pd/C, EtOH.
[26]. However, some combination of the above strategies may like-
wise be an effective route for the development of novel derivatives
with potent therapeutic activity.
The present review mainly focuses on the syntheses and brief
pharmacological studies of hormone-derived molecules containing
different substituents, including various side-chains or heterocyclic
moieties, fused to or linked to the original sterane framework,
which have been reported to exhibit an in vitro cell growth-
inhibitory effect on malignant tumor cell lines.
2. Synthesis and antiproliferative activity of
estrane-derived compounds
2ME2 has been evaluated under the name Panzem® in sev-
eral clinical trials. The clinical results demonstrated that 2ME2
is metabolized principally in oxidative and conjugation processes
involving oxidation of the 17-hydroxy group and glucuronidation of
both the 3- and 17-hydroxy functions [27]. These transformations
lead to a rapid decrease in the concentration of the active drug,
resulting in its low bioavailability. Moreover, in vitro metabolism
studies have indicated that the methoxy moiety of 2ME2 can be
removed oxidatively by the action of cytochromes P450 to form
2-hydroxyestradiol, which could be estrogenic in vivo. Thus, appre-
ciable efforts have been made to synthesize modiﬁed analogs with
an enhanced ability to inhibit tubulin polymerization or with an
antiproliferative effect, but if possible without estrogenic activ-
ity, thereby providing an improvement in the metabolic proﬁle.
In attempts to elucidate the determinants of 2ME2 activity and to
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yridine,  CH2Cl2; (iv) (1) Pd(OAc)2, rac-BINAP, benzophenone imine, Cs2CO3, toluen
hen  acidic workup, (3) NaBH4, MeOH; (vi) (1) BrCN, Et2O, CH2Cl2, (2) NaBH4, MeOH
or  34a; Ac2O, NaOH (10 M aqueous) for 34b.
repare more efﬁcacious analogs, structure–activity relationship
SAR) studies have been conducted by several research groups.
ost of these studies have concentrated on modifying existing
ubstituents or incorporating new substituents in rings A and D
f 2ME2,  although some B ring-expanded derivatives have also
een found to exert noteworthy activity [28]. The introduction
f an additional double-bond(s) into ring D of 2ME2 enhanced
he in vitro antiproliferative activity on the MDA-MB-435 (human
reast carcinoma) and SK-OV-3 (ovarian carcinoma) cell lines as
ompared with the parent molecule [29]. Compounds 4 and 10
ere synthesized via well-known transformations from a common
recursor 2, available from the 3-benzyloxy analog 1 [30] of 2ME2
Scheme 1). Interestingly, some unsaturated derivatives 9 and 13,
hich lack the 17-hydroxy group, were also demonstrated to retain
ell growth-inhibitory effects on both endothelial and tumor cells
31,32]. Moreover, in vitro metabolic stability studies have con-
rmed that these analogs are metabolically more stable than 2ME2
32].
18a-Homoanalogs of 2ME2 synthesized by Rao et al. [33] from
4 via a multistep pathway (Scheme 2) and some of them, such
s 22 and 24 were demonstrated to exhibit cytotoxic activity
n MDA-MB-231 (human breast carcinoma), U87-MG (human
liomablastoma) and HUVEC (human umbilical vein endothelial)
ells that was higher than or comparable to that of 2ME2.  The intro-
uction of a 14-bond in 22,  however, signiﬁcantly lowered the
iological activity.) K-t-amylate, RPPh3Br; (ii) hydrazine, KOH, diethylene glycol, nBuOH; (iii) Tf2O,
 M HCl, THF; (v) (1) Pd(OAc)2, rac-BINAP, Cs2CO3, dppp, HMDS, DMF, CO, (2) MeOH,
 NaOCN, H2O, AcOH; (viii) LiAlH4 (1 M in THF); (ix) (1) formic acid, (2) NaOH, MeOH
Structural modiﬁcations including ring D homologation and
aromatization of the six-membered ring D to a chrysine-type
molecule were also carried out through a cumbersome synthetic
sequence to furnish novel derivatives with considerable antiprolif-
erative effects [31].
Since the 3- and 17-hydroxy groups play a crucial role in the
metabolic pathways of 2ME2,  modiﬁcations of these functionali-
ties have also been performed in order to obtain analogs with a
retained or improved cell growth-inhibitory effect, but with dimin-
ished metabolic ability. The transformations depicted in Scheme 3
were carried out from 2-methoxyestrone (11) to furnish novel
derivatives 25–27 lacking the 17-hydroxy moiety or containing an
aminonitrile (31), urea (32), formamide (34a), carboxamide (30),
amino (33) or acetamide (34b) group on C-3 [32,34]. All these
compounds were found to exert diminished estrogenic activity,
improved metabolic stability and increased or similar antiprolifer-
ative and antiangiogenic activity relative to 2ME2.  It was concluded
that, among other factors, the H-donating ability, the -electronic
character and the size of the C-3 substituent all determine the bio-
logical activity.
The simultaneous modiﬁcations of positions 3 and 17 in 2ME2
also led to active analogs (Scheme 4) [35]. Compounds 13 and
25–27, obtained from 2-methoxyestrone (11) by Shapiro reduction
(13), Wittig coupling (25 and 26)  or Wolf–Kishner reduction (27)
(Schemes 1 and 2), were used for the syntheses. All the synthesized
derivatives represented by 40–42 and 45–47 exhibited marked cell
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Scheme 4. Synthesis of 3,17-bis-modiﬁed analogs of 2ME2.  Reagents and conditions:  (i) Tf O, pyridine; (ii) PdCl , dppp, CO, HMDS, DMF, MeOH,  then acidic workup; (iii)
P  BrCN
g
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S
Hd(OAc)2, rac-BINAP, Cs2CO3, benzophenone imine, toluene, then 2 M HCl, THF; (iv)
rowth inhibition, but carboxamide analogs 40 and 41 were found
o be 3- to 6-fold more potent in antiproliferative activity and 3-
o 5-fold more potent in antiangiogenic activity as compared with
ME2. Moreover, all the carboxamides 40–42 possessed signiﬁ-
antly better in vivo pharmacokinetic properties in mice than those
f 2ME2.
Some 3,17-bis-modiﬁed analogs of 2ME2 containing sulfamate
roup(s) at position(s) 3 and/or 17 were also found to dis-
lay potent antiproliferative effects [36–38]. These agents inhibit
H
H H
X
BnO
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i
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cheme 5. Synthesis of 16-modiﬁed analogs of 2ME2.  Reagents and conditions: (i) NH2NM
2, Pd/C, EtOAc.2 2
, Et2O, CH2Cl2.
steroid sulfatase, carbonic anhydrase, cancer cell proliferation and
angiogenesis. Replacement of OMe  with an ethyl group on C-2 led
to derivatives with increased potency.
It has been demonstrated that substitution of C-16 in 2ME2 with
small alkyl groups leads to active derivatives [39]. The addition
of steric and/or electronic bulk at this position was assumed to
prevent or slow oxidation and/or conjugation at position 17 and
consequently improve the antiangiogenic and antitumor effects
observed for 2ME2 in vivo. For the transformations, 2ME2 was  ﬁrst
H
H H
X
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MeO
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50, 51 X = N-NMe2
52, 53 X = O
iii
H
H H
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MeO
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56, 57 R2 = H
v
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e2, EtOH, DMF; (ii) nBuLi, THF, R1I; (iii) CuCl2·2H2O; THF/H2O; (iv) LiAlH4; THF; (v)
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pcheme 6. Synthesis of 2-modiﬁed and 2,17-bis-modiﬁed analogs of 2ME2.  Reagent
eOH,  KOH; (iii) CH3P+Ph3I− , NaH, DMSO; (iv) EtMgBr, (CH2O)n , THF, HMPA; (v) (1
rotected as benzyl ether with K2CO3/benzyl bromide in ethanol,
nd then oxidized to 3-O-benzyl-2-methoxyestrone (48) under
wern conditions [40]. The 16-substituted compounds 56 and 57
ere prepared from 48 as starting material in multistep pathways
Scheme 5). Methyl and ethyl substitution were well tolerated for
ntiproliferative activity against MDA-MB-231 breast tumor cells,
ut 56 was found to be more estrogenic than 2ME2.
Since steric and electronic factors at position 2 are prominent
ontributors to the cytotoxicity and the antitubulin activity of 2ME2
nd its analogs [41], certain 2-substituted and 2,17-bis-modiﬁed
nalogs were prepared in an effort to improve the biological activ-
ty of 2ME2 (Scheme 6) [42]. Among the various synthesized
ompounds, some chalcone (60, 63)  and 2-alkylamino derivatives
64a–h) were found to exhibit in vitro antiproliferative activities
omparable with that of the parent analog against four human can-
er cell lines [HCT-116 (colon), NCIH-460 (lung), U-251 (glioma),
B-435 (breast)].
The above-mentioned results led to further investigations being
irected toward the synthesis of novel estrane-type antipro-
iferative agents. Thus, 15-methylestrone-3-methyl ether (69),
vailable from estrone (65), was demonstrated to inhibit the
iability of MGC-803 (human gastric) cancer cells, similarly to
oxorubicin (Scheme 7) [43]. The key step of the reaction sequence
nvolved the stereoselective conjugate addition of a methyl group
erived from Me3Al into 68 under CuBr catalysis. Zupko et al.
ave reported that a D-ring-expanded analog of estrone, com-
ound 74,  which can be synthesized in three steps from aonditions: (i) (1) NaBH4, THF, MeOH, (2) EtMgBr, (CH2O)n , THF, HMPA; (ii) ArCOCH3,
2, Na2SO4, DMF, (2) NaBH4, MeOH.
d-secoestrone-aldehyde 70,  exerts a cytostatic effect on HeLa
(human cervix epitheloid carcinoma) cells that is similar to that
of cisplatin, but its selectivity toward noncancerous cells is signiﬁ-
cantly better than that of the reference compound [44]. Moreover,
in vitro pharmacological studies conﬁrmed modulation of the
cell cycle progression through the promotion of several steps of
apoptosis, and the lack of signiﬁcant estrogenic activity [25]. d-
Dihomologation by Barbier allylation – ring-closing metathesis,
however, led to a derivative 77 with merely moderate antiprolifer-
ative activity [45].
3. Synthesis and antiproliferative activity of
androstane-derived compounds
As compared with the estrane-derived semisynthetic molecules,
for fewer examples are to be found in the literature as concerns
the synthesis of simpler substituted androstane derivatives that
exert cytostatic activity. Although dehydroepiandrosterone (78),
the most abundant adrenal androgenic steroid in young adult
humans, and its endogenous metabolites have been demonstrated
to possess chemopreventive and antiproliferative effects [46,47],
clariﬁcation of the exact mechanisms of their action is still required.
Nevertheless, intensive searches for more potent and less andro-
genic androstane derivatives are ongoing. In this respect, the
synthetic 3-ester 80 and 3-ether analog 81 of 78 have been found to
exert promising antiproliferative activity toward a prostate cancer
cell line (DU-145) associated with a better antiandrogenic effect
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han that of the reference control ﬁnasteride (Scheme 8) [48].
jurendic´ et al. [49] investigated the cell growth-inhibitory effects
f some d-homolactone derivatives of 78,  and a 6-nitro compound
4 proved to show high selectivity toward a prostate cancer cell
ine (PC-3) and low toxicity against normal fetal ﬁbroblasts (MRC-
).
Some 7-methyl-substituted 4-3-ones (88 and 94), synthe-
ized in a highly stereoselective manner from their dienone
recursors (87 and 93)  by 1,6-conjugate addition, were reported
o exhibit similar cytostatic activities on gastric cancer cell line
GC-803 to that of the reference doxorubicin (Scheme 9) [43].
. Synthesis and antiproliferative activity of
ormone-derived heterocyclic compoundsBesides the introduction of simple substituents onto the sterane
keleton, the construction of heterocyclic moieties either con-
ected to or condensed with the original framework offers another
ossibility of obtaining analogs possessing antitumor activity. Theents and conditions: (i) Bu4N+I− , MeI, CH2Cl2, NaOH; (ii) (iPr)2NH, THF, nBuLi, Et3N,
 (vi)  Jones reagent, acetone; (vii) H2, Pd/C, EtOAc; (viii) allyl bromide, Zn, THF; (ix)
most frequent synthetic modiﬁcations are performed on C-3, C-17
or C-20, or on the carbon atoms adjacent to the already substituted
C-3, C-17 or C-20 due to the simple implementation. Substitution
at other positions of the sterane skeleton has proved to be more dif-
ﬁcult, necessitating several reaction steps, and is therefore rarely
applied. Steroidal heterocycles containing various numbers of ring
nitrogen atoms will be discussed bellow.
4.1. Steroidal heterocycles containing one ring nitrogen atom
Compounds that inhibit the enzyme aromatase have found
applications in the treatment of advanced ER+ breast cancer. In
recent years, highly potent and speciﬁc aromatase inhibitors have
been developed [50,51]. A nonsteroidal inhibitor of aromatase,
rogletimid (3-ethyl-3(4-pyridyl)piperidine-2,6-dione), contains a
pyridine ring as an important constitutive element [52]. Accord-
ingly steroidal 17-picolyl 96 and 17-picolinylidene 97 and 98
derivatives were synthesized from dehydroepiandrosterone (78),
and their Oppenauer oxidation led to the corresponding 4-3-
ketosteroids 100 and 103 (Scheme 10), which similarly proved to be
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yridine; (iii) iPrOH; (iv) Ac2O; pyridine; (v) HNO3, NaNO2, Et2O.
romatase inhibitors [53]. In investigations of the relation between
he aromatase inhibitory effect and the antitumor activity, there-
ore, some modiﬁed derivatives were tested on three tumor cell
ines: MCF-7 (ER+ human breast adenocarcinoma), MDA-MB-231
ER− human breast adenocarcinoma) and PC3 (prostate cancer).
oth the N-oxides 99 and 104 prepared from 97 and 103, respec-
ively, by oxidation with m-chloroperoxybenzoic acid (MCPBA),
nd also the starting material 96 were found to exert strong
ntiproliferative activity against PC3, with IC50 values in the range
.55–10 M,  while the 4,5-epoxide 102 obtained from 100 on
eaction with H2O2 in alkaline medium displayed a marked cell
rowth-inhibitory effect against MDA-MB-231 [54]. It additionally
merged that the 16-keto analogs of 97 and 98 [55,56] effectively
nhibited the proliferation of HeLa, FemX (human melanoma) and
562 (human myelogenous leukemia) cells [53].
Besides picolyl derivatives, various steroidal isoxazolidines and
soxazoles were synthesized and investigated for their antiprolif-
rative activity. The thermally induced intramolecular 1,3-dipolar
ycloadditions of a d-secopregnene aldehyde (105) (obtained from
regnadienolone acetate [57]) with N-substituted hydroxylamines
urnished N-functionalized isoxazolidines 107 diastereoselectively,
ia the corresponding alkenyl nitrones 106 (Scheme 11). When the
ytostatic effects of the 3-deacetylated compounds 108 were tested
n vitro, the N-benzyl-substituted derivative (R2 = Bn) displayed the
ighest activity on HeLa cells, with an IC50 value comparable to that
f the reference cisplatin [58].Steroidal 17-isoxazoles in the estrane series were also pre-
ared by 1,3-dipolar cycloaddition (Scheme 12). The CuI-catalyzed
egioselective ring closures of different aryl nitrile oxides with mes-
ranol (109) afforded the exo-heterocyclic products 110 in good to activity. Reagents and conditions: (i) p-TsCl, pyridine; (ii) 4-chlorobenzoyl chloride,
excellent yields [59,60]. These novel isoxazolyl derivatives, which
lack an estrogenic effect [61], were subjected to in vitro phar-
macological studies in order to investigate their antiproliferative
effects on three malignant human gynecological cell lines. The ﬂuo-
rinated analog 110 (R = p-F) and the p-nitro-substituted derivative
110 (R = p-NO2) proved to be the most promising compounds as
concerns cell growth inhibition.
4.2. Steroidal heterocycles containing two ring nitrogen atoms
Investigations of the antiproliferative activities of this type of
compounds have mainly focused on derivatives containing a pyra-
zoline moiety. An efﬁcient and facile synthesis of 17-pyrazolinyl
derivates was  reported by Banday et al. [62]. The reaction sequence
involved the conversion of pregnenolone (111) to benzylidene
derivatives 112 with (substituted) benzaldehyde(s), and the subse-
quent ring closures of 112 with hydrazine in the presence of acetic
acid (Scheme 13). Although the newly formed stereogenic center
at C-5′ can allow the formation of two  epimers (113 and 114),
the products were tested as the unseparated mixtures on seven
human cancer cell lines [HT-29, HCT-15 (colon), 502,713 (colon),
HOP-62, A-549 (lung), MCF-7 (breast) and SF-259 (CNS)]. The IC50
values of the diastereomeric products (113 + 114) indicated that
some of the compounds (R = m-F, p-F, o-CH3, m-CH3 and p-OMe)
exerted signiﬁcant cytotoxic activity, especially against the colon
cell lines. Moreover, the cytotoxicity of the analogs for certain can-
cer cell lines varied more than 100-fold on change of the position
of a given substituent on the aromatic ring (e.g. R = o-OMe vs. R = p-
OMe). Following the synthetic route indicated above, Iványi et al.
prepared further pyrazolinyl derivatives, which could be separated,
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uBr,  TMSCl, THF; (iv) Ac2O, AcCl; (v) NBS, LiBr, Li2CO3.
ut only in their acetylated forms (115 and 116) [63]. The deacety-
ated isomers 113 and 114 were tested separately on four cancer
ell lines: HeLa (cervix), MCF7 (breast), A2780 (ovarian) and A431
skin), but their antiproliferative potencies were not comparable
ith those of the reference cisplatin. However, it should be noted
hat substantial differences were found in the in vitro results on the
iastereomeric pairs: the 5′S epimers 114 were more potent than
heir 5′R counterparts 113.
As regards the six-membered N,N-heterocycles, Poirier et al.
64,65] reported the synthesis of a large set of 2-(N-substituted
iperazino)-5-androstane derivatives and several compounds
ere found to inhibit the proliferation of HL-60 human leukemia
ells.
Besides simple heteroring substitution, another possibility for
he design of cytostatic steroidal agents is the construction of
olecules structurally similar to natural steroid alkaloids. Plants
re among the most varied and promising sources of new anti-
ancer drugs, as they contain compounds which are produced by
peciﬁc enzyme-catalyzed processes that differ signiﬁcantly from
hose in animals and humans. Some of these alkaloid analogs are
nown to have cytotoxic properties [66] or to act as chemosensitiz-
rs in multidrug resistance [67]; consequently, structurally related
ompounds may  have similar or even improved biological activ-
ty. In this respect, an efﬁcient approach has been reported to novel
ndrostene-fused arylpyrazolines that can be regarded as synthetic
olanidine analogs, and these compounds were tested for their
ntiproliferative activities [26,68]. The highly diastereoselective
ewis acid-induced intramolecular 1,3-dipolar cycloadditions of
lkenylphenylhydrazones 117 obtained from d-secopregnene alde-
yde 105 resulted in D-ring-fused products 118 in good to excellentonditions:  (i) tetrachlorobenzoquinone, tBuOH; (ii) Ac2O, DMAP, CH2Cl2; (iii) Me3Al,
yields (Scheme 14). The ability of phenylhydrazones 117 to undergo
cyclization was  found to be affected signiﬁcantly by the electronic
features of the substituents (R1) on the aromatic moiety. Both
the experimental ﬁndings and theoretical calculations indicated
that the cycloadditions follow a stepwise rather than a pure con-
certed mechanism. The antiproliferative activities of the pyrazoline
derivatives 118 and 119 were tested in vitro on three malig-
nant human cell lines (HeLa, MCF7 and A431): the microculture
tetrazolium assay (MTT) revealed that several compounds exerted
marked cell growth-inhibitory effects. The highest cytostatic activ-
ities, displayed by the p-methoxyphenylpyrazoline derivative 119
(R1 = p-OMe), were better than those of cisplatin. Moreover, this
compound inhibited the proliferation of normal human ﬁbroblast
cells (MRC-5) at a one order of magnitude higher concentration
(IC50 = 17.01 M)  than for HL-60 leukemia cells (IC50 = 1.27 M),
reﬂecting its efﬁciently selective cytotoxic activity [69]. Further
pharmacological studies indicated that 119 (R1 = p-OMe) promoted
a marked disturbance in the cell cycle, and induced the manifes-
tation of the markers of early apoptosis and secondary necrosis,
which was  in part a consequence of its inhibitory effect on the
activity of ribonucleotide reductase.
4.3. Steroidal heterocycles containing three ring nitrogen atoms
Among the heterocyclic systems, triazole often demonstrates
some special activity when it is introduced into biological active
compounds [70–72]. Moreover, the basicity and hydrophilicity of
this moiety might alter the pharmacological function of a steroid.
With regard to these facts, therefore, a number of steroidal tri-
azoles have been synthesized during the past few years, through
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Scheme 10. Synthesis of some picolyl-substituted derivatives. Reagents and cond
l(tBuO)3, cyclohexanone; (vi) H2O2, NaOH, MeOH.
 click chemistry approach. The synthetic routes involve the
ntroduction of an azido group into any position of the sterane
ramework and the subsequent ring closure of the steroidal azide
ith a terminal acetylene in the presence of a Cu(I) source. Cu(I)-
atalyzed azide–alkyne cycloaddition (CuAAC) is convenient for
he regioselective construction of 1,4-disubstituted triazoles in
hich the heterocycle is attached directly to the steroid nucleus
hrough a nitrogen atom, or these two moieties are connected
o each other through a linker. The reaction has further advan-
ageous beneﬁts, such as high yields of the desired products,
olerability to a variety of common parameters (functional groups,
olvents, pH and temperature), the lack of by-products and insen-
itivity to the steric and electronic properties of the reactants
73–75].
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cheme 11. Synthesis of D-ring-fused isoxazolidines by thermally induced 1,3-dipolar cy (i) -PyCH2Li, THF; (ii) Ac2O; (iii) KOH, MeOH; (iv) MCPBA, CH2Cl2, NaHCO3; (v)
The simplest procedures for the formation of steroidal azides
are either the modiﬁcation of extant functional groups (C-3, C-
17 or C-20) in the original hormone analog or substitution at
adjacent positions (C-2, C-16 or C-21). Thus, Bandy et al. [76]
recently reported a facile synthesis of 21-triazolyl derivatives of
pregnenolone by using an in situ one-pot CuAAC (Scheme 15). In
this case the triazolyl moiety is attached to the steroid nucleus
through a methylene ketone linkage. The synthesis started from
pregnenolone (111), which was  treated with Br2/MeOH in the
dark to furnish 21-bromopregnenolone (120) in good yield. The
in situ two-step conversion of 120 in the presence of NaN3, CuSO4,
sodium ascorbate and the appropriate alkyne in a 1:1 mixture of
tert-butanol and water resulted in 21-triazolylpregnenolone
derivatives 121a–g. These compounds were screened in vitro for
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cloaddition. Reagents and conditions: (i) R2NHOH, NaOAc, MeOH;  (ii) KOH, MeOH.
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Scheme 12. Synthesis of 17-isoxazoles by Cu(I)-catalyzed 1,3-dipolar cycloaddition. Reagents and conditions:  (i) CuI, Ph3P, DIPEA, toluene.
HO
H
H H
111
O
HO
H
H H
O
R1
112
R2O
H
H H
N
N
Ac
R1
113 (5'R) + 114 (5'S) R2 = H
115 (5'R) + 116 (5'S) R2 = Ac
5'
R1 = H, F, Cl, Me, OMe [59]
R1 = H, F, Cl, Br, CN, OMe [60]
i
ii
iii
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Br,  Br2, MeOH; (ii) NaN3, CuSO4·5H2O, Na ascorbate, tBuOH, H2O, HC CCH2OC6H
yridine; (v) NaN3, DMF; (vi) R2C CH, CuSO4·5H2O, Na ascorbate, CH2Cl2, H2O; (vi
heir activity against seven human cancer cell lines, i.e. DU-145, PC-
 (prostate), SF-295 (CNS), HCT-15, 502713 (colon), HEP-2 (liver)
nd A-549 (lung), using the sulforhodamine B assay. The IC50 val-
es revealed that 121e (R = p-OMe) exerted signiﬁcant cytotoxicity
gainst the PC-3, HCT-15 and 502713 cell lines, while the other
erivatives were found to be effective against all these diverse can-
er cell lines.
Kádár et al. [77] recently prepared 1,2,3-triazolyl derivatives
n the androstane series in which the heterocycle is con-
ected to C-16 of the sterane framework through a methylene
roup. The Claisen condensation of 3-acetoxyandrost-5-en-
7-one (122) with ethyl formate in the presence of NaOMe
nd the subsequent acetylation/reduction sequence led to
hree 3-acetoxy-16-hydroxymethyl-17-diols, from which theal group (C-17) or in nearby (C-16 or C-21) positions. Reagents and conditions: (i)
ii) (1) ethyl formate, NaOMe, toluene, (2) Ac2O, pyridine, (3) KBH4,  EtOH; (iv)  TsCl,
, MeOH; (viii) KBH4, MeOH, CH2Cl2; (ix) R2C CH, CuI, Ph3P, CH2Cl2.
16-hydroxymethyl-17-hydroxy isomer 123 was separated
(Scheme 15). After conversion of the primary hydroxyl group of
123 to p-toluenesulfonate derivative 124, nucleophilic substitution
with NaN3 was  carried out to furnish the corresponding azide 125.
Various aryl, heteroaryl and cycloalkyl-substituted triazoles 126
were then synthesized by the CuACC of 125 with various terminal
alkynes, CuSO4·5H2O serving as Cu(I) source in reductive medium.
For the cyclizations, a mixture of dichloromethane as solvent and
water as co-solvent was  employed to eliminate the need for lig-
ands and to simplify the reaction protocol [78]. The antiproliferative
activities of the deacetylated analogs (127) were determined in
vitro with the MTT  assay on three gynecological cell lines (HeLa,
MCF-7 and A2780). Compound 127, containing a 3-methylphenyl
group on the triazolyl moiety, was  found to exert a marked cell
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(cheme 16. Construction of triazolyl moieties at unconventional (C-1 and C-15) p
for  134), ArC CH (for 137) or RC CH (for 140), CuI, Ph3P, DIPEA, (3) Jones reagent
rowth-inhibitory effect on A2780 cells, while the 2-pyridyl deriva-
ive proved effective on HeLa cells.
The preparation of novel 17-triazoles in which the hetero-
ycle is attached directly to ring D of the sterane core has also
een reported recently [24]. For the CuAACs, steroidal 17-azide
31, readily available from 5-androst-2-en-17-one (128) in a
hree-step pathway, was used as starting material (Scheme 15).
tereoselective reduction of the 17-keto group, leading to 129, was
ollowed by tosylation to give 130, which then underwent facile
N2 substitution with NaN3 to furnish the corresponding 17-azido
ompound 131. The ring closures of 131 with different terminal
cetylenes were carried out in reﬂuxing dichloromethane with CuI
s catalyst in the presence of Ph3P. Although determination of the
fﬁnities for the hormonal receptors did not fall within the scope
f the work, in the absence of a keto functional group at position
-3, the newly prepared triazolyl derivatives were considered not
o possess an androgenic effect. The in vitro pharmacological tests
ndicated that 132, containing a cyclopropyl group (R2) on its het-
rocycle, possessed the highest activity, causing 82–98% growth
nhibition on all malignant cell lines (HeLa, MCF7 and A431) at
0 M,  and was therefore comparable to the reference compound
isplatin. Interestingly, the similar transformations in the estrane
eries led to 17-triazoles that generally exhibited lower pharma-
ological activities.
Further triazolyl derivatives were synthesized in both the
strane and the androstane series, in which the triazolyl moiety
as situated at the unconventional C-15 position [79]. First, an
zido group was introduced stereoselectively onto position 15
f sterane skeleton of the unsaturated ketones 68 and 135 by the
,4-Michael addition of azoimide [80], generated in situ from NaN3
nd acetic acid, to afford azidoketones 133 and 136 in good yields
Scheme 16). After subsequent reduction of the 17-keto group ins. Reagents and conditions: (i) NaN3, AcOH, THF; (ii) (1) KBH4, MeOH, (2) PhC CH
ne.
order to avoid elimination, the resultant steroidal cis-azidoalcohols
were reacted with different terminal alkynes. The best conversions
were observed on the use of a catalytic amount of CuI with Ph3P as
stabilizing ligand and excess N,N-diisopropyl ethylamine (DIPEA)
as amine base in reﬂuxing toluene. The following Jones oxidation
afforded the corresponding 17-keto 15-triazolyl derivatives 134
and 137 in both the estrane and the androstane series. The antipro-
liferative activities of the synthesized compounds were determined
by using three malignant adherent cell lines (HeLa, MCF7 and A431)
in the MTT  assay, in comparison with cisplatin as positive control.
15-Triazolylestrone methyl ether (133) and its 17-hydroxy analog
exhibited marked antiproliferative effects against A431 cells, while
the 5-androstane counterpart (137) exerted similar or higher
activities on HeLa and MCF7 cells than these of cisplatin. Since sub-
stantial differences were not detected between the IC50 values of
the different aryl-substituted derivatives of 137, it was concluded
that the substituent on the triazolyl ring does not have a crucial
impact on the anticancer capacities of this skeleton. Further bio-
chemical and morphological results indicated that the initiation of
apoptosis predominated in the antiproliferative action of the tested
compounds.
After a systematic study of D-ring-substituted triazolyl com-
pounds, a number of analogous derivatives were prepared in which
the triazoles were connected to ring A [81]. Starting from unsatu-
rated ketone 138, an azido group was introduced onto position 1
of the sterane skeleton by Michael addition, which resulted stere-
oselectively in the 1-azido isomer 139 due to the steric bulk of
the neighboring angular methyl group. 1-Triazolyl-17-oxo deriva-
tives 140 were obtained in a rather roundabout way following the
reduction– CuAAC–oxidation sequence. These derivatives exerted
outstanding cytotoxic activity on HeLa cells, characterized by IC50
values between 1 and 2 M,  i.e.  one order of magnitude lower than
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hat of the reference cisplatin. On the other hand, the cell lines
CF7 and A2780 seemed to be much less sensitive to 140 than to
isplatin.
. Summary
The routes available to date for the synthesis of sex
ormone-derived steroidal compounds that display marked cell
rowth-inhibitory effects on one or more cancer cell lines of
iverse origins have been discussed. The results achieved so far
emonstrate that the introduction of either simple substituents
r heterocyclic moieties may  alter the biological activities of the
arent compounds signiﬁcantly, and the application of suitable
odiﬁcations can eliminate the undesirable hormonal properties.
hus, both structure-based drug design and a more random search
or effective derivatives appear to deserve attention in the quest for
ovel steroidal anticancer agents.
cknowledgments
This work was supported ﬁnancially by the New Hungary Devel-
pment Plan (TÁMOP TÁMOP-4.2.2.A-11/1/KONV-2012-0047) and
he Hungarian Scientiﬁc Research Fund (K 101659). The project
TÁMOP 4.2.1/B-09/1/KONV-2010-0005 – Creating the Center of
xcellence at the University of Szeged′′ is supported by the Euro-
ean Union and co-ﬁnanced by the European Regional Fund.
eferences
[1] G. Guerriero, Vertebrate sex steroid receptors: evolution, ligands, and neurodis-
tribution, Annals of the New York Academy of Sciences 1163 (2009) 154–168.
[2] M.K. Thakur, V. Paramanik, Role of steroid hormone coregulators in health and
disease, Hormone Research 71 (2009) 194–200.
[3]  G.M. Anstead, K.E. Carlson, J.A. Katzenellenbogen, The estradiol pharma-
cophore: ligand structure–estrogen receptor binding afﬁnity relationships and
a  model for the receptor binding site, Steroids 62 (1997) 268–303.
[4] A.G. Fragkaki, Y.S. Angelis, M.  Koupparis, A. Tsantili-Kakoulidou, G. Kokotos,
C.  Georgakopoulos, Structural characteristics of anabolic androgenic steroids
contributing to binding to the androgen receptor and to their anabolic and
androgenic activities. Applied modiﬁcations in the steroidal structure, Steroids
74  (2009) 172–197.
[5] A. Hillisch, J. von Langen, B. Menzenbach, P. Droescher, G. Kaufmann, B. Schnei-
der,  W.  Elger, The signiﬁcance of the 20-carbonyl group of progesterone in
steroid receptor binding: a molecular dynamics and structure-based ligand
design study, Steroids 68 (2003) 869–878.
[6] A.C. Herington, L.K. Chopin, P. Jeffery, L. de Amorim, T. Veveris-Lowe, L. Bui,
J.A. Clements, Hormone-dependent cancers: new approaches to identiﬁcation
of  potential diagnostic and/or therapeutic biomarkers, Asia-Paciﬁc Journal of
Molecular Biology and Biotechnology 18 (2010) 63–66.
[7] N. Zhu, Y. Ling, X. Lei, V. Handratta, A.M.H. Brodie, Novel P45017 inhibitors: 17-
(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstane derivatives, Steroids 68 (2003)
603–611.
[8] J.P. Burkhart, C.A. Gates, M.E. Laughlin, R.J. Resvick, N.P. Peet, Inhibition of
steroid C17(20) lyase with C-17-heteroaryl steroids, Bioorganic and Medicinal
Chemistry 4 (1996) 1411–1420.
[9] D. Ondré, J. Wölﬂing, I. Tóth, M.  Szécsi, J. Julesz, Gy Schneider, Stereo-
selective synthesis of some steroidal oxazolines, as potential inhibitors of
17-hydroxylase-C17,20-lyase, Steroids 74 (2009) 1025–1032.
10] Y.Z. Ling, J.S. Li, Y. Liu, K. Kato, G.T. Klus, A.M.H. Brodie, 17-Imidazolyl, pyra-
zolyl and isoxazolyl androstene derivatives, novel steroid inhibitors of human
cytochrome (C17,20-lyase (P45017), Journal of Medicinal Chemistry 40 (1997)
3297–3304.
11] Z. Iványi, J. Wölﬂing, T. Görbe, M.  Szécsi, T. Wittmann, Gy Schneider, Synthesis of
regioisomeric 17-N-phenylpyrazolyl steroid derivatives and their inhibitory
effect on 17-hydroxylase/C17,20-lyase, Steroids 75 (2010) 450–456.
12] A.M.H. Brodie, V.C.O. Njar, Aromatase inhibitors and their application in breast
cancer treatment, Steroids 65 (2000) 171–179.
13] M.R. Yadav, P.M. Sabale, R. Giridhar, C. Zimmer, J. Haupenthal, R.W. Hartmann,
Synthesis of some novel androstanes as potential aromatase inhibitors, Steroids
76 (2011) 464–470.
14] V.C. Jordan, Tamoxifen: toxicities and drug resistance during the treatment and
prevention of breast cancer, Annual Review of Pharmacology and Toxicology
35  (1995) 195–211.
15] V.S. Pribluda, E.R. Gubish, T.M. LaVallee, A. Treston, G.M. Swartz, J.S. Green,
2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug
candidate, Cancer and Metastasis Reviews 19 (2000) 173–179.
[try & Molecular Biology 137 (2013) 301– 315
16] L.R. Quadan, C.M. Perez-Stable, C. Anderson, G. D’lppolito, A. Herron, G.A.
Howard, A.B. Roos, 2-Methoxyestradiol induces G2/M arrest and apoptosis in
prostate cancer, Biochemical and Biophysical Research Communications 285
(2001) 1259–1266.
17] T.-L. Yue, X. Wang, C.S. Louden, S. Gupta, K. Pillarisetti, J.-L. Gu, T.K. Hart, P.G.
Lysko, Z.G. Feuerstein, 2-Methoxyestradiol, an endogenous estrogen metabo-
lite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible
role for stress-activated protein kinase signaling pathway and Fas expression,
Molecular Pharmacology 51 (1997) 951–962.
18] H. Seeger, F.-U. Deuringer, D. Wallwiener, A.O. Mueck, Breast cancer risk during
HRT: inﬂuence of estradiol metabolites on breast cancer and endothelial cell
proliferation, Maturitas 49 (2004) 235–240.
19] A.O. Mueck, H. Seeger, 2-Methoxyestradiol—biology and mechanism of action,
Steroids 75 (2010) 625–631.
20] T. Mqoco, S. Marais, A. Joubert, Inﬂuence of estradiol analogue on cell growth,
morphology and death in esophageal carcinoma cells, Biocell 34 (2010)
113–120.
21] A.O. Mueck, C. Lippert, H. Seeger, D. Wallwiener, Angiogenetic and antiangio-
genetic effects of estradiol and its metabolites, Journal of Clinical and Basic
Cardiology 4 (2001) 153–155.
22] T.M. LaVallee, X.H. Zhan, C.J. Herbstritt, E.C. Kough, S.J. Green, S.V. Pribluda, 2-
Methoxyestradiol inhibits proliferation and induces apoptosis independently
of  estrogen receptors  and , Cancer Research 62 (2002) 3691–3697.
23] N.J. Lakhani, M.A. Sarkar, J. Venitz, D.W. Figg, 2-Methoxyestradiol, a promising
anticancer agent, Pharmacotherapy 23 (2003) 165–172.
24] É. Frank, J. Molnár, I. Zupkó, Z. Kádár, J. Wölﬂing, Synthesis of novel steroidal
17-triazolyl derivatives via Cu(I)-catalyzed azide–alkyne cycloaddition, and
an  evaluation of their cytotoxic activity in vitro, Steroids 76 (2011) 1141–1148.
25] J. Wölﬂing, E. Mernyák, É. Frank, G. Falkay, Á. Márki, R. Minorics, Gy Schneider,
Synthesis and receptor-binding examinations of the normal and 13-epi-d-
homoestrones and their 3-methyl ethers, Steroids 68 (2003) 277–288.
26] É. Frank, Zs. Kardos, J. Wölﬂing, Gy Schneider, Stereoselective synthesis of novel
5-androstenopyrazoline derivatives by BF3 ·OEt2-induced intramolecular 1,3-
dipolar cycloaddition, Synlett (2007) 1311–1313.
27] N.J. Lakhani, A. Sparreboom, X. Xu, T.D. Veenstra, J. Venitz, W.L. Dahut, W.D.
Figg, Characterization of in vitro and in vivo metabolic pathways of the inves-
tigational anticancer agent, 2-methoxyestradiol, Journal of Pharmaceutical
Sciences 96 (2007) 1821–1831.
28] Z. Wang, D. Yang, A.K. Mohanakrishnan, P.E. Fanwick, P. Nampoothiri, E. Hamel,
M.  Cushman, Synthesis of B-ring homologated estradiol analogues that mod-
ulate tubulin polymerization and microtubule stability, Journal of Medicinal
Chemistry 43 (2000) 2419–2429.
29] P.N. Rao, J.W. Cessac, T.L. Tinley, S.L. Mooberry, Synthesis and antimitotic activ-
ity of novel 2-methoxyestradiol analogs, Steroids 67 (2002) 1079–1089.
30] P.N. Rao, J.W. Cessac, A new, practical synthesis of 2-methoxyestradiols,
Steroids 67 (2002) 1065–1070.
31] P.N. Rao, J.W. Cessac, J.W. Boyd, A.D. Hanson, J. Shah, Synthesis and antimi-
totic activity of novel 2-methoxyestradiol analogs. Part III, Steroids 73 (2008)
171–183.
32] J.H. Shah, G.E. Agoston, L. Suwandi, K. Hunsucker, V. Pribluda, X.H. Zhan,
G.M. Swartz, T.M. LaVallee, A.M. Treston, Synthesis of 2- and 17-substituted
estrone analogs and their antiproliferative structure–activity relationships
compared to 2-methoxyestradiol, Bioorganic and Medicinal Chemistry 17
(2009) 7344–7352.
33] P.N. Rao, J.W. Cessac, J.W. Boyd, A.D. Hanson, J. Shah, Synthesis and antimi-
totic activity of novel 2-methoxyestradiol analogs. Part II, Steroids 73 (2008)
158–170.
34] L.S. Suwandi, G.E. Agoston, J.H. Shah, A.D. Hanson, X.H. Zhan, T.M. LaVallee, A.M.
Treston, Synthesis and antitumor activities of 3-modiﬁed 2-methoxyestradiol
analogs, Bioorganic and Medicinal Chemistry Letters 19 (2009) 6459–6462.
35]  G.E. Agoston, J.H. Shah, L. Suwandi, A.D. Hanson, X. Zhan, T.M. LaVallee, V.
Pribluda, A.M. Treston, Synthesis, antiproliferative, and pharmacokinetic prop-
erties of 3- and 17-double-modiﬁed analogs of 2-methoxyestradiol, Bioorganic
and Medicinal Chemistry Letters 19 (2009) 6241–6244.
36] M.P. Leese, F.L. Jourdan, K. Gaukroger, M.F. Mahon, S.P. Newman, P.A. Foster,
et  al., Structure–activity relationships of C-17 cyano-substituted estratrienes
as anticancer agents, Journal of Medicinal Chemistry 51 (2008) 1295–1308.
37] C. Bubert, M.P. Leese, M.F. Mahon, E. Ferrandis, S. Regis-Lydi, P.G. Kasprzyk,
S.P. Newman, et al., 3,17-Disubstituted 2-alkylestra-1,3,5(10)trien-3-ol deriva-
tives: synthesis, in vitro and in vivo anticancer activity, Journal of Medicinal
Chemistry 50 (2007) 4431–4443.
38] F. Jourdan, M.P. Leese, W.  Dohle, E. Hamel, E. Ferrandis, S.P. Newman,
et al., Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-
methoxyestradiol-3,17-O,O-bis-sulfamate, Journal of Medicinal Chemistry 53
(2010) 2942–2951.
39] G.E. Agoston, J.H. Shah, T.M. LaVallee, X. Zhan, V.S. Pribluda, A.M. Treston,
Synthesis and structure–activity relationships of modiﬁed analogs of 2-
methoxyestradiol, Bioorganic and Medicinal Chemistry 15 (2007) 7524–7537.
40] A.J. Mancuso, S.-L. Huang, D. Swern, Oxidation of long-chain and related alco-
hols to carbonyls by dimethyl sulfoxide “activated” by oxalyl chloride, Journal
of  Organic Chemistry 43 (1978) 2480–2482.41] A.B. Edsall, A.K. Mohanakrishnan, D. Yand, P.E. Fanwick, E. Hamel, A.D.
Hanson, G.E. Agoston, M.  Cushman, Effects of altering the electronics of 2-
methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell
cultures, and on tubulin polymerization, Journal of Medicinal Chemistry 47
(2004) 5126–5139.
hemis
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[É. Frank, G. Schneider / Journal of Steroid Bioc
42] G. Panchapakesan, V. Dhayalan, N.D. Moorthy, N. Saranya, A.K. Mohanakrish-
nan, Synthesis of 2-substituted 17-hydroxy/17-methylene estratrienes and
their in vitro cytotoxicity in human cancer cell cultures, Steroids 76 (2011)
1491–1504.
43] C. Li, W.  Qiu, Z. Yang, J. Luo, F. Yang, M.  Liu, J. Xie, J. Tang, Stereoselective synthe-
sis  of some methyl-substituted steroid hormones and their in vitro cytotoxic
activity against human gastric cancer cell line MGC-803, Steroids 75 (2010)
859–869.
44] R. Minorics, N. Bózsity, J. Wölﬂing, E. Mernyák, Gy. Schneider, Á. Márki, G.
Falkay, I. Ocsovszki, I. Zupkó, Antiproliferative effect of normal and 13-epi-
d-homoestrone and their 3-methyl ethers on human reproductive cancer cell
lines, Journal of Steroid Biochemistry 132 (2012) 168–175.
45] T. Saloranta, I. Zupkó, J. Rahkila, Gy. Schneider, J. Wölﬂing, R. Leino, Increasing
the  amphiphilicity of an estradiol based steroid structure by Barbier-
allylation—ring-closing metathesis—dihydroxylation sequence, Steroids 77
(2012) 110–117.
46] S. Yoshida, A. Honda, Y. Matsuzaki, S. Fukushima, N. Tanaka, A. Takagiwa, Y.
Fujimoto, H. Miyazaki, G. Salen, Anti-proliferative action of endogenous dehy-
droepiandrosterone metabolites on human cancer cell lines, Steroids 68 (2003)
73–83.
47] Y. Matsuzaki, A. Honda, Dehydroepiandrosterone and its derivatives:
potentially novel anti-proliferative and chemopreventive agents, Current Phar-
maceutical Design 12 (2006) 3411–3421.
48] N. Dhingra, T.R. Bhardwaj, N. Mehta, T. Muklopadhyay, A. Kumar, M.  Kumar,
Synthesis, antiproliferative activity, acute toxicity and assessment of the
antiandrogenic activities of new androstane derivatives, Archives of Pharmacal
Research 34 (2011) 1055–1063.
49] E.A. Djurendic´, M.P. Zavisˇ, M.N. Sakacˇ, J.J. Cˇanadi, V.V. Kojic´, G.M. Bogdanovic´,
K.M. Penov Gasˇi, Synthesis and antitumor activity of new d-seco and d-homo
androstane derivatives, Steroids 74 (2009) 983–988.
50] R.J. Santen, Inhibition of aromatase: insight from recent studies, Steroids 72
(2007) 31–40.
51] R.W. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz, Aromatase inhibitors in the
treatment of breast cancer, Endocrine Reviews 26 (2005) 331–345.
52] R. McCague, M.G. Rowlands, Conformational analysis of the aromatase
inhibitor 3-ethyl-3(4-pyridyl)piperidine-2,6-dione (Rogletimide) and discov-
ery of potent 5-alkyl derivatives, Journal of Medicinal Chemistry 35 (1992)
3699–3704.
53] K.M.P. Gasˇi, M.D.D. Brenesel, E.A. Djurendic´, M.N. Sakacˇ, J.J. Daljev, T. Arm-
bruster, S. Andric´, D.M. Sladic´, T.T. Bozˇic´, I.N. Novakovic´, Z.D. Juranic´,  Synthesis
and biological evaluation of some 17-picolyl and 17-picolinylidene androst-5-
ene derivatives, Steroids 72 (2007) 31–40.
54] E. Djurendic´, J. Daljev, M.  Sakacˇ, J. Cˇanadi, S.J. Sˇanta, S. Andric´, O. Klisuric´, V.
Kojic´,  G. Bogdavovic´, M.  Djurendic´-Brenesel, S. Novakovic´, K.P. Gasˇi, Synthesis
of  some epoxy and/or N-oxy 17-picolyl and 17-picolinylidene-androst-5-ene
derivatives and evaluation of their biological activity, Steroids 73 (2008)
129–138.
55] D. Miljkovic´, K. Gasˇi, M.  Kindjer, S. Stankovic´, B. Ribar, Partial syntheses of
21,27-bisnordemissidine from epiandrosterone and dehydroepiandrosterone
acetates. Crystal and molecular structure of 21,27-bisnordemissidine hydro-
bromide, Croatica Chemica Acta 58 (1985) 721–736.
56] D. Miljkovic´, K. Gasˇi, 3-Acetoxy-17-picolinylidene-5-androstene-16-one: the
key intermediate in 21,27-bisnorsolanidine synthesis, Bulletin de la Société
Chimique Beograd 46 (1981) 263–268.
57] J. Wölﬂing, A. Magyar, Gy. Schneider, Synthesis of novel d-seco-pregnenes,
Monatshefte fur Chemie 134 (2003) 1387–1393.
58] É. Frank, Z. Mucsi, M.  Szécsi, I. Zupkó, J. Wölﬂing, Gy. Schneider, Intramolecular
approach to some new D-ring-fused steroidal isoxazolidines by 1,3-dipolar
cycloaddition: synthesis, theoretical and in vitro pharmacological studies, New
Journal of Chemistry 34 (2010) 2671–2681.
59] F. Himo, T. Lowell, R. Hilgraf, V.V. Rostovtsev, L. Noodleman, K.B. Sharpless,
V.V. Fokin, Copper(I)-catalyzed synthesis of azoles, DFT study predicts unprece-
dented reactivity and intermediates, Journal of the American Chemical Society
127 (2005) 210–216.
60] D. Kovács, Z. Kádár, G. Mótyán, Gy. Schneider, J. Wölﬂing, I. Zupkó, É. Frank, Syn-
thesis, characterization and biological evaluation of some novel 17-isoxazoles
in  the estrone series, Steroids 77 (2012) 1075–1085.61] Ch Camoutsis, S. Nikolaroupoulos, Steroidal isoxazoles, isoxazolines and isox-
azolidines, Journal of Heterocyclic Chemistry 35 (1998) 731–759.
62] A.H. Banday, B.P. Mir, I.H. Lone, K.A. Suri, H.M.S. Kumar, Studies on novel D-
ring substituted steroidal pyrazolines as potential anticancer agents, Steroids
75  (2010) 805–809.
[try & Molecular Biology 137 (2013) 301– 315 315
63] Z. Iványi, N. Szabó, J. Huber, J. Wölﬂing, I. Zupkó, M.  Szécsi, Gy. Schneider,
Synthesis of D-ring-substituted (5′R)- and (5′S)-17-pyrazolinylandrostene
epimers and comparison of their potent anticancer activities, Steroids 77 (2012)
566–574.
64] D. Thibeault, J. Roy, P. DeRoy, D. Poirier, Chemical synthesis of 2-amino-
5-androstane-3,17-diol N-derivatives and their antiproliferative effect on
HL-60 human leukemia cells, Bioorganic and Medicinal Chemistry 16 (2008)
5062–5077.
65] J. Roy, R. Maltais, H. Jegham, D. Poirier, Libraries of 2-(N-substituted
piperazino)-5-androstane-3,17-diols: chemical synthesis and cytotoxic
effects on human leukemia HL-60 cells and on normal lymphocytes, Molecular
Diversity 15 (2011) 317–339.
66] K.R. Lee, N. Kozukue, J.S. Han, J.H. Park, E.Y. Chang, E.J. Baek, J.S. Chang, M.  Fried-
man, Glycoalkaloids and metabolites inhibit the growth of human colon (HT29)
and liver (HepG2) cancer cells, Journal of Agricultural and Food Chemistry 52
(2004) 2832–2839.
67] Y. Lavie, T. Harel-Orbital, W.  Gafﬁeld, M.  Liscovitch, Inhibitory effect of steroidal
alkaloids on drug transport and multidrug resistance in human cancer cells,
Anticancer Research 21 (2001) 1189–1194.
68] É. Frank, Z. Mucsi, I. Zupkó, B. Réthy, G. Falkay, Gy.  Schneider, J. Wölﬂing, Efﬁ-
cient approach to androstene-fused arylpyrazolines as potent antiproliferative
agents. experimental and theoretical studies of substituent effects on BF3-
catalyzed intramolecular [3 + 2] cycloadditions of oleﬁnic phenylhydrazones,
Journal of the American Chemical Society 131 (2009) 3894–3904.
69] R. Minorics, T. Szekeres, G. Krupitza, P. Saiko, B. Giessrigl, J. Wölﬂing, É. Frank,
I.  Zupkó, Antiproliferaive effects of some novel synthetic solanidine analogs on
HL-60 human leukemia cells in vitro, Steroids 76 (2011) 156–162.
70] D.R. Buckle, C.J. Rockell, H. Smith, B.A. Spicer, Piperazinylalkoxy[1]
benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-
antihistamine and mast cell stabilizing properties, Journal of Medicinal
Chemistry 29 (1986) 2262–2267.
71] R. Alvarez, S. Velazquez, A. San-Felix, S. Aquaro, E. De Clercq, C.F. Perno, et al.,
1,2,3-Triazole-[2′ ,5′-bis-O-(tertbutyldimethylsilyl)-beta-d-ribofuranosyl]-
3′-spiro-5′′-(4′′-amino-1′′ ,2′′-oxathiole 2′′ ,2′′-dioxide) (TSAO) analogues:
synthesis and anti-HIV-1 activity, Journal of Medicinal Chemistry 37 (1994)
4185–4194.
72] V.C.O. Njar, G.T. Klus, A.M.H. Brodie, Nucleophilic vinylic “addition-elimination”
substitution reaction of 3-acetoxy-17-chloro-16-formylandrosta-5,16-diene:
a novel and general route to 17-substituted steroids. Part 1. Synthesis
of novel 17-azolyl-16 steroids; inhibitions of 17-hydroxylase/17,20-
lyase (17-lyase), Bioorganic and Medicinal Chemistry Letters 6 (1996)
2777–2782.
73] V.V. Rostovtsev, L.G. Green, V.V. Fokin, K.B. Sharpless, A stepwise Huisgen
cycloaddition process: copper(I)-catalyzed regioselective ligation of azides
and  terminal alkynes, Angewandte Chemie International Edition 41 (2002)
2596–2599.
74] C.W. Tornøe, C. Christensen, M.  Meldal, Peptidotriazoles on solid phase: [1,2,3]-
triazoles by regiospeciﬁc copper(I)-catalyzed 1,3-dipolar cycloadditions of
terminal alkynes to azides, Journal of Organic Chemistry 67 (2002) 3057–3064.
75] M.  Meldal, C.W. Tornøe, Cu(I)-catalyzed azide–alkyne cycloaddition, Chemical
Reviews 108 (2008) 2952–3015.
76] A.H. Banday, S.A. Shameem, B.D. Gupta, H.M.S. Kumar, D-ring substituted
1,2,3-triazolyl 20-keto pregnanes as potential anticancer agents: synthesis and
biological evaluation, Steroids 75 (2010) 801–804.
77] Z. Kádár, D. Kovács, É. Frank, Gy. Schneider, J. Huber, I. Zupkó, T.
Bartók, J. Wölﬂing, Synthesis and in vitro antiproliferative activity of novel
androst-5-ene triazolyl and tetrazolyl derivatives, Molecules 16 (2011)
4786–4806.
78] B.Y. Lee, S.R. Park, H.B. Jeon, K.S. Kim, A new solvent system for efﬁcient syn-
thesis of 1,2,3-triazoles, Tetrahedron Letters 47 (2006) 5105–5109.
79] Z. Kádár, J. Molnár, Gy. Schneider, I. Zupkó, É. Frank, A facile “click” approach
to  novel 15-triazolyl-5-androstane derivatives and an evaluation of their
antiproliferative activities in vitro, Bioorganic and Medicinal Chemistry 20
(2012) 1396–1402.
80] I. Cherny, V. Pouzar, O. Lapcik, R. Hampl, Addition of azoimide to unsaturated
ketones in the steroid series—synthesis of (oxy-3-oxo-5-androstan-15-
yl)succinamoic acid and its evaluation as hapten for dihydrotestosterone
immuno analysis, Collection of Czechoslovak Chemical Communications 62
(1997) 1931–1939.
81] Z. Kádár, Á. Baji, I. Zupkó, T. Bartók, J. Wölﬂing, É. Frank, Efﬁcient approach
to novel 1-triazolyl-5-androstane derivatives as potent antiproliferative
agents, Organic & Biomolecular Chemistry 9 (2011) 8051–8057.
